Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 78,553 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at $44,150,756.13. The trade was a 22.69 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, November 15th, Steven Leonard Chapman sold 4,728 shares of Natera stock. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48.
• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The shares were sold at an average price of $118.21, for a total transaction of $468,111.60.

Natera Stock Up 2.7 %

NTRA traded up $4.47 during midday trading on Wednesday, reaching $171.93. The company’s stock had a trading volume of 2,052,001 shares, compared to its average volume of 1,460,392. The stock’s 50-day moving average is $165.35 and its 200-day moving average is $135.41. Natera, Inc. has a 1 year low of $62.96 and a 1 year high of $183.00. The firm has a market capitalization of $22.70 billion, a price-to-earnings ratio of -97.69 and a beta of 1.65. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same quarter last year, the company earned ($0.95) EPS. The firm’s revenue for the quarter was up 63.9% on a year-over-year basis. As a group, research analysts expect that Natera, Inc. will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Natera

Hedge funds have recently bought and sold shares of the company. Blue Trust Inc. boosted its stake in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Quarry LP increased its holdings in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares in the last quarter. Versant Capital Management Inc raised its position in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the last quarter. Covestor Ltd lifted its stake in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NTRA shares. TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird increased their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. upped their price objective on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. The Goldman Sachs Group raised their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Finally, StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $160.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.